Aphidius ervi

Hauptinformation

  • Handelsname:
  • Aphidius ervi
  • Verwenden für:
  • Pflanzen
  • Art der Medizin:
  • Agrochemisch

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Aphidius ervi
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Lebende Organismen (Insekten)

Weitere Informationen

Status

  • Quelle:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Zulassungsnummer:
  • W-6495
  • Letzte Änderung:
  • 06-09-2017

Packungsbeilage

Produkt:

Handelsbezeichnung: Aphidius ervi

Produktekategorie

Bewilligungsinhaber Eidg. Zulassungsnummer

Lebende Organismen (Insekten) Omya (Schweiz) AG W-6495

Stoff(e)

Gehalt

Formulierungscode

Wirkstoff: Aphidius ervi

XA Adulte

Anwendungen

A Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

G Gewächshaus: allg.

Grünfleckige

Kartoffelblattlaus

Grünstreifige

Kartoffelblattlaus

Aufwandmenge: 0.5 - 4 Organismen/m²

Anwendung: Beim Auftreten der ersten

Blattläuse oder Saugschäden.

1, 2, 3, 4

gedeckte Kulturen:

allg.

Grünfleckige

Kartoffelblattlaus

Grünstreifige

Kartoffelblattlaus

Aufwandmenge: 0.5 - 4 Organismen/m²

Anwendung: Beim Auftreten der ersten

Blattläuse oder Saugschäden.

1, 2, 3, 4

Auflagen und Bemerkungen:

Die Beratung über den Einsatz und die Qualitätskontrolle der Nützlinge muss durch die Import-

und Vertriebsfirma sichergestellt werden.

Vor und während der Freilassungen ist eine sorgfältige Befallsüberwachung dringend zu

empfehlen. Auch der Nützlingsbestand sollte regelmässig kontrolliert werden. Vor der Freilassung

darf während einer angemessenen Frist kein nützlingsgefährdendes Produkt eingesetzt werden.

Die Wirkungseffizienz der Nützlinge kann je nach Pflanzenart stark schwanken.

Auf der Produktetikette ist die Anzahl Organismen pro Packung anzugeben.

Gefahrenkennzeichnungen:

SP 1 Mittel und/oder dessen Behälter nicht in Gewässer gelangen lassen.

Im Zweifelsfall gelten einzig die Originaldokumente der Zulassung. Die Erwähnung eines Produktes,

Wirkstoffes oder einer Firma stellt keine Empfehlung dar und bedeutet nicht, dass sich das Produkt im

Verkauf befindet.

18-7-2018

Orphan designation:  Gevokizumab,  for the: Treatment of chronic non-infectious uveitis

Orphan designation: Gevokizumab, for the: Treatment of chronic non-infectious uveitis

On 12 March 2013, orphan designation (EU/3/13/1111) was granted by the European Commission to Les Laboratoires Servier, France, for gevokizumab for the treatment of chronic non-infectious uveitis.

Europe - EMA - European Medicines Agency

18-7-2018

Hy-Vee Voluntarily Recalls Spring Pasta Salad Due to Reported Illnesses

Hy-Vee Voluntarily Recalls Spring Pasta Salad Due to Reported Illnesses

WEST DES MOINES, Iowa (July 17, 2018) — Hy-Vee, Inc., based in West Des Moines, Iowa, is voluntarily recalling its Hy-Vee Spring Pasta Salad due to the potential that it may be contaminated with Salmonella. The potential for contamination was brought to Hy-Vee’s attention last night when approximately 20 illnesses in Minnesota, South Dakota, Nebraska and Iowa were potentially linked back to customers consuming the salad. The voluntary recall includes Hy-Vee Spring Pasta Salads in both 1 pound (16 oz.) an...

FDA - U.S. Food and Drug Administration

12-7-2018

Minimum service during 23 July - 3 August

Minimum service during 23 July - 3 August

Due to summer holidays minimum service level will be at the Icelandic Medicines Agency from 23 July till 3 August, both days included. Please note that the agency is closed on Monday 6 August due to a bank holiday.

IMA - Icelandic Medicines Agency

2-7-2018

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services is voluntarily recalling two (2) lots of Neostigmine Methylsulfate 5mL syringes to the user/hospital/clinic level. The specified product lots are being recalled because of a confirmed customer complaint that some syringe units containing Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL are incorrectly labelled as Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL. Secondary packages are properly labelled as Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

24-5-2018

Reference Delegation Day: an annual meeting of the reference laboratories

Reference Delegation Day: an annual meeting of the reference laboratories

Every year, ANSES brings together all the French holders of the national reference laboratory and European Union reference laboratory mandates, with support from the Joint Laboratory Service of the fraud control and customs services. This delegation day aims to improve cooperation and sharing of experience, and symbolises the importance of reference work to ANSES's missions.

France - Agence Nationale du Médicament Vétérinaire

16-5-2018

Mas Food Services Co. Issues Allergy Alert on Undeclared Sulfites in The Peruchef Dry Potato

Mas Food Services Co. Issues Allergy Alert on Undeclared Sulfites in The Peruchef Dry Potato

Mas Food Services Co. of Oakland Park, FL is recalling its 15 ounce packages of The Peruchef brand dry potato because it may contain undeclared sulfites. People who have an allergy or severe sensitivity to sulfites run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

8-5-2018

Veterinary Feed Directive (VFD)

Veterinary Feed Directive (VFD)

A VFD drug is intended for use in animal feeds, and such use of the VFD drug is permitted only under the professional supervision of a licensed veterinarian.

FDA - U.S. Food and Drug Administration

4-1-2016

The Danish Medicines Agency has a new website

The Danish Medicines Agency has a new website

Today, the Danish Medicines Agency launched its new website – laegemiddelstyrelsen.dk/en – where you can read about and subscribe to news about licensing and supervision of medicines, side effects, reimbursement, pharmacies and medical devices.

Danish Medicines Agency

16-3-2015

New management at the DHMA

New management at the DHMA

As from 13 March 2015, Jakob Cold has been appointed Acting Director General of the Danish Health and Medicines Authority. Anne-Marie Vangsted will continue as Director with special responsibility for the DHMA's supervision.

Danish Medicines Agency

3-2-2015

New director at the DHMA

New director at the DHMA

On 1 February 2015, Anne-Marie Vangsted, Acting Head of Division, took up the position as Director with responsibility for supervision at the Danish Health and Medicines Authority. The new position as director was created as part of our action plan aimed at modernising the supervisory function, in which Anne-Marie Vangsted has played a key role since we presented the plan on 15 September 2014.

Danish Medicines Agency

5-1-2015

Fees for medical devices in 2015

Fees for medical devices in 2015

The fees for medical devices have been adjusted in accordance with Danish Government regulations, including the fees for registration of manufacturers and devices, importers and distributors, assessment of applications for the authorisation for clinical investigation of medical devices, and amendments to investigations, as well as supervision and control of notified bodies in Denmark.

Danish Medicines Agency

29-8-2018

Cinryze (Shire Services BVBA)

Cinryze (Shire Services BVBA)

Cinryze (Active substance: C1 inhibitor, human) - Centralised - Yearly update - Commission Decision (2018)5767 of Wed, 29 Aug 2018

Europe -DG Health and Food Safety

29-8-2018

Nucala (GlaxoSmithKline Trading Services Limited)

Nucala (GlaxoSmithKline Trading Services Limited)

Nucala (Active substance: mepolizumab) - Centralised - 2-Monthly update - Commission Decision (2018)5770 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3860/II/13/G

Europe -DG Health and Food Safety

28-8-2018

EU/3/18/2065 (SFL Regulatory Services GmbH)

EU/3/18/2065 (SFL Regulatory Services GmbH)

EU/3/18/2065 (Active substance: Obiltoxaximab) - Orphan designation - Commission Decision (2018)5735 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/080/18

Europe -DG Health and Food Safety

7-8-2018

EU/3/16/1694 (GlaxoSmithKline Trading Services Limited)

EU/3/16/1694 (GlaxoSmithKline Trading Services Limited)

EU/3/16/1694 (Active substance: Autologous CD4+ and CD8+ T-cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1) - Transfer of orphan designation - Commission Decision (2018)5405 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/064/16/T/01

Europe -DG Health and Food Safety

4-8-2018

EU/3/18/2053 (Lakeside Regulatory Consulting Services Ltd)

EU/3/18/2053 (Lakeside Regulatory Consulting Services Ltd)

EU/3/18/2053 (Active substance: Tamibarotene) - Orphan designation - Commission Decision (2018)5285 of Sat, 04 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/026/18

Europe -DG Health and Food Safety

1-8-2018

Strimvelis (GlaxoSmithKline Trading Services Limited)

Strimvelis (GlaxoSmithKline Trading Services Limited)

Strimvelis (Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) - Centralised - Yearly update - Commission Decision (2018)5217 of Wed, 01 Aug 2018

Europe -DG Health and Food Safety

25-7-2018

Eperzan (GlaxoSmithKline Trading Services Limited)

Eperzan (GlaxoSmithKline Trading Services Limited)

Eperzan (Active substance: albiglutide) - Centralised - Yearly update - Commission Decision (2018)4982 of Wed, 25 Jul 2018

Europe -DG Health and Food Safety

27-6-2018

Dzuveo (FGK Representative Service GmbH)

Dzuveo (FGK Representative Service GmbH)

Dzuveo (Active substance: sufentanil) - Centralised - Authorisation - Commission Decision (2018)4097 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4335

Europe -DG Health and Food Safety

25-6-2018

Rolufta (GlaxoSmithKline Trading Services Limited)

Rolufta (GlaxoSmithKline Trading Services Limited)

Rolufta (Active substance: umeclidinium) - Centralised - Yearly update - Commission Decision (2018)4017 of Mon, 25 Jun 2018

Europe -DG Health and Food Safety

20-6-2018

Share your thoughts with us in the 2018 TGA surveys

Share your thoughts with us in the 2018 TGA surveys

Our annual survey measures satisfaction with a range of services and activities including our role and performance

Therapeutic Goods Administration - Australia

29-5-2018

EU/3/09/699 (Cambridge Regulatory Services Ltd)

EU/3/09/699 (Cambridge Regulatory Services Ltd)

EU/3/09/699 (Active substance: Recombinant chimeric monoclonal antibody against CD20) - Transfer of orphan designation - Commission Decision (2018)3399 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/090/09/T/01

Europe -DG Health and Food Safety

24-5-2018

Osseor (Les Laboratoires Servier)

Osseor (Les Laboratoires Servier)

Osseor (Active substance: Strontium ranelate) - PASS - Modification - Commission Decision (2018)3271 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSR/S/13

Europe -DG Health and Food Safety

24-5-2018

Protelos (Les Laboratoires Servier)

Protelos (Les Laboratoires Servier)

Protelos (Active substance: Strontium ranelate) - PASS - Modification - Commission Decision (2018)3270 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSR/S/13

Europe -DG Health and Food Safety

17-5-2018

#ThrowBackThursday: May 17, 1971- The Public Health Service Bureau of Radiological Health transferred to FDA. It’s Mission: Protect against unnecessary human exposure to radiation from electronic products in the home and industry. #OnThisDay #FDAHistory

#ThrowBackThursday: May 17, 1971- The Public Health Service Bureau of Radiological Health transferred to FDA. It’s Mission: Protect against unnecessary human exposure to radiation from electronic products in the home and industry. #OnThisDay #FDAHistory

#ThrowBackThursday: May 17, 1971- The Public Health Service Bureau of Radiological Health transferred to FDA. It’s Mission: Protect against unnecessary human exposure to radiation from electronic products in the home and industry. #OnThisDay #FDAHistory

FDA - U.S. Food and Drug Administration

16-5-2018

EU/3/13/1116 (GlaxoSmithKline Trading Services Limited)

EU/3/13/1116 (GlaxoSmithKline Trading Services Limited)

EU/3/13/1116 (Active substance: Mepolizumab) - Transfer of orphan designation - Commission Decision (2018)3046 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/174/12/T/01

Europe -DG Health and Food Safety

16-5-2018

EU/3/04/213 (GlaxoSmithKline Trading Services Limited)

EU/3/04/213 (GlaxoSmithKline Trading Services Limited)

EU/3/04/213 (Active substance: Mepolizumab) - Transfer of orphan designation - Commission Decision (2018)3045 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/027/04/T/02

Europe -DG Health and Food Safety

15-5-2018

PecFent (Kyowa Kirin Services Ltd)

PecFent (Kyowa Kirin Services Ltd)

PecFent (Active substance: Fentanyl ) - PSUSA - Modification - Commission Decision (2018)3007 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1164/PSUSA/1369-201704

Europe -DG Health and Food Safety

23-4-2018

GMP clearance process improvements - Post implementation update

GMP clearance process improvements - Post implementation update

GMP Clearance Process - Common issues when completing the online application form in TGA Business Services

Therapeutic Goods Administration - Australia

28-3-2018

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Transfer of orphan designation - Commission Decision (2018)2011 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/17/T/01

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/1989 (FGK Representative Service GmbH)

EU/3/18/1989 (FGK Representative Service GmbH)

EU/3/18/1989 (Active substance: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide) - Orphan designation - Commission Decision (2018)1878 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/208/17

Europe -DG Health and Food Safety